Osteonecrosis of the Jaw Related to Oral Bisphosphonate Treatment: A Clinical Case
DOI:
https://doi.org/10.17140/DOJ-1-105Abstract
Bisphosphonates are inhibitors of osteoclastic activity and hence cause inhibition of
bone resorption.1-3 These drugs, which are synthetic analogy of natural pyrophosphate, have
proven their effectiveness in the treatment of diverse metabolic bone diseases related to quantitative
alterations, as is the case of osteoporosis,4-6 or qualitative ones, as in Paget’s disease.7
The most common way for their administration is orally.5 These anti-resorptive drugs cause an
increase of bone mineral density and a quick decrease of fracture risk.8-13 They are also effective
in oncology patients (breast cancer, prostate cancer, lung cancer, and multiple myeloma, among
others).14-19 Additionally, these medicines reduce the symptoms of bone pathology (bone pain,
delay of the first new bone event, reduction in fracture appearance).4,17-19 They are normally administered
intravenously. Bisphosphonates have anti-cancer effect alone or in combination with
other chemotherapy treatments, as they maximize antineoplastic effects.20 In pediatrics, they are
used in the treatment of diseases related to abnormal calcinosis or ectopic bone formation, as is
the case of osteogenesis imperfect.
References
Vicente Rodríguez JC, Junquera Gutiérrez LM. Osteoquimio-necrosis of the jaws induced by bisphosphonates. In: Machin Muñiz JA, ed. How to identify, prevents, and treat complica-tions in implant dentistry. SA, Madrid, USA: Editorial Ripano; 2012: 385-397.
Ruggiero SL, Mehrotra B, RosenbergTj, Engroff SL. Osteo-necrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62: 527- 534. doi: 10.1016/j.joms.2004.02.004
Bocanegra-Pérez S, Limiñana-Cañal JM, Vicente-Barrero M, et al. Bisphosphonates in primary care. Epidemiological study of management and impact of bisphosphonates in patients at-tending dental offices of the Canary Islands Health Service. Ad-vances in dentistry. 2010; 26(3). 143-151.
Department of Pharmacy and Health Products. Recommenda-tions for the assessment and treatment of primary osteoporosis in women of the Community of Madrid. Madrid, USA: 2008.
Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 2003; 19: 395-414.
Baron R. Anatomy and Biology of Bone Matrix and Cellu-lar Elements General Principles of Bone Biology. Primer on the metabolic bone diseases and disorders of mineral research. Washington, DC, USA: 2003.
Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacohter. 2005; 39: 668-677. doi: 10.1345/aph.1E357
Cranney A, Welch V, Adachi JD, et al. Etidronate for treat-ing and preventing postmenopausal osteoporosis (Cochrane review): In Cochrane Library. Chichesster, UK: John Wiley & sons, Ltd. 2004; 2. doi: 10.1002/14651858.CD003376.pub2
Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Os-teoporos Int. 2001; 12: 140-151.
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alen-dronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Os-teoporosis Treatment Study Group. N Engl J Med. 1995; 333: 1437-1443. doi: 10.1056/NEJM199511303332201
Black DM, Cummings SR, Karpf DB, et al. Randomized tri-al of effect of alendronate on risk of fracture in women with ex-isting vertebral fractures. Fracture Intervention Trial Research-Group. Lancet. 1996: 1535-1541. doi: http://dx.doi.org/10.1016/ S0140-6736(96)07088-2
Harris ST, Watts NB, Genant HK, et al. Effects of rise-dronate treatment on vertebral and non-vertebral fractures in women with post menopauesel osteoporosis: A randomised con-trolled trial. JAMA. 1999; 282(14): 1344-1352. doi: 10.1001/ jama.282.14.1344
Reginster JY, Minnie HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000; 11: 83-91.
Lunch A, Pérez Fidalgo JA, Chirivella I. Indications of bisphosphonates. In: Bagan JV, ed. Osteonecrosis of the jaw by bisphosphonates. USA: Valencia Oral Medicine SL; 2008: 1-110.
Sosa Henriquez M, Gómez de Tejeda de Romero MJ, Bagán Sebastián JV, et al. Osteonecrosis of the Jaws: Consensus docu-ment. Rev Osteoporos. Metab Miner. 2009; 1(1): 41-51.
Bagán JV, Diz Dios P, Gallego L, et al. Recommendations for prevention of osteonecrosis of the jaw (ONJ) in cancer pa-tients treated with intravenous bisphosphonates. Oral Med Oral Pathol Oral Cir. 2008; 13(3): 161-167.
Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of biphosponates in solid tumours: recommendations of an International expert panel. Ann Oncol. 2008; 19(3): 420-432. doi: 10.1093/annonc/mdm442
Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with ad-vanced multiple myeloma. N Engl J Med. 1996; 334: 488-493. doi: 10.1056/NEJM199602223340802
Berenson JR, Rosen LS, Howell A, et al. Zoledron-ic acid reduces skeletal-related events in patients with os-teolytic metastases. Cancer. 2001; 91: 1191-1200. doi: 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119> 3.0.CO;2-0
Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid in-hibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25(7): 829- 836. doi: 10.1200/JCO.2005.05.3744
Yeste D, Carrascosa A, Audi L. Pathophysiology of calcium-phosphorus metabolism. In: Argente J, Carrascosa A, Gracia R, Rodriguez F. eds. In the Treaty of Pediatric Endocrinology and Adolescencia. Madrid, USA: Edimsa; 1995: 551-565.
Reeder J, MS, PA-C, Orwoll E, MD. Adults with OI. N Engl J Med. 2006; 355.
Glorieux FH. Cyclic administration of pamidronate therapy in children with severe osteogenesis imperfecta. N Engl J Med. 1998; 339: 947-952. doi: 10.1056/NEJM199810013391402
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003; 61: 1115-1117. doi: 10.1016/ S0278-2391(03)00720-1
Sosa Henriquez M, Gómez de Tejeda de Romero MJ, Bagán Sebastián JV, et al. Osteonecrosis de los Maxilares: Documento de consenso. Rev Osteoporos Metab Miner. 2009; 1: 41-51.
Spanish Agency for Medicines and Health Products. Infor-mation Note (ref 2005/17). Parenteral bisphosphonates and os-teonecrosis of the jaw. Disponible en: http://www.agemed.es/ actividad/alertas/docs/NI_2005-17.pdf
Spanish Agency for Medicines and Health Products. Infor-mation Note (ref 2005/17). Parenteral bisphosphonates and os-teonecrosis of the jaw. Recomendaciones para la prevención de la osteonecrosis maxilar asociada al tratamiento con bisfosfonatos. Available at: http://www.agemed.es/actividad/alertas/usoHuma-no/seguridad/NI_2009-10_bisfosfonatos.htm 2005; Accessed 2014.
American Association of Oral and Maxillofacial Surgeons. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecro-sis of the jaws. J Oral Maxillofac Surg. 2007; 65: 369-376.
Junquera LM. Diagnosis, prevention and treatment of os-teonecrosis of the jaw by bisphosphonates. Recommendations of the Spanish Society of Oral and Maxillofacial Surgery (SEC-OM). Cient Dent. 2008; 5(3): 229-237.
Marx RE, Cillo JE, Ulloa JJ. Oral Bisphosphonate induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007; 65: 2397-2410. doi: 10.1016/j.joms.2007.08.003
Reid IR. Osteonecrosis of the jaw: Who gets it, and why? Bone. 2009; 44: 4-10. doi: 10.1016/j.bone.2008.09.012
Reid I. Patogénesis of osteonecrosis of the jaw. IBMS Bonekey. 2008; 2: 69-77.
Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol. 2009; 38: 107.
Cartsos VM, Zarvas AI. Bisphosphonate use and the risk of adverse jaw outcomes: A medical claims study of 714,217 people. J Am Dent Assoc. 2008; 139: 23-30. doi: 10.14219/jada. archive.2008.0016
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphospho-nate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral MaxillofacSurg. 2005; 63: 1567-1575. doi: 10.1016/j. joms.2005.07.010
Marx RE, Sawatari Y, Fortin M, Broumand V. Risk factors, recognition, prevention, treatment of Bisphosphonate-induced osteonecrosis of the jaws. J Oral Maxillofac Surg. 2006; 64: 96.
Bagán JV. La osteonecrosis de los maxilares por bifosfona-tos. Valencia. Medicina oral SL. 2008; 1-110.
Reid IR, Grey AB. Is Bisphosphonate-associated osteone-crosis of the jaw caused by soft tissue toxicity? Bone. 2007; 41: 318-320. doi: 10.1016/j.bone.2007.04.196
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associeted osteonecrosis of the jaw: report of a task force of the Ameri-can Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22: 1479-1491. doi: 10.1359/jbmr.0707onj
Bisphosphonates: Osteonecrosis of the jaw. Drug Safety Up-date. 2009; 3(4): 2-3.
Acero J, Burgueño M, de Vicente JC, et al. Diagnóstico, Prevención y tratamiento de la osteonecrosis de los maxilares por bifosfonatos. Recomendaciones de la Sociedad Española de Cirugía Oral y Maxilofacial (SECOM). Comisión Artículo ex-traido de la Revista Española de Cirugía Oral y Maxilofacial. Madrid, mayo-junio de. 2008; 30(3): 145-156.
Jiménez Soriano Y, Roda P. Prevention of Osteonecrosis of the jaw by bisphosphonates. In: Bagan JV, ed. Osteonecrosis of the jaw by bisphosphonates. Valencia, Spain: Medicina oral SL; 2008: 1-110.
Ruggiero S, Fantasia J, Carlson E. Bisphosphonate- related osteonecrosis of the jaw: Background and guidelines for diagno-sis skating and Management. Oral Surg Oral Med Oral Pathol. 2006. 102(4): 433-441. doi: 10.1016/j.tripleo.2006.06.004
Gallego L, Junquera L. Consequence of therapy discontinu-ation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg. 2009; 47: 67-68. doi: 10.1016/j. bjoms.2008.05.011
Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment pro-posals. Am J Otolaryngol. 2007; 28: 158-163. doi: 10.1016/j. amjoto.2006.08.004
Barker K, Rogers S. Bisphosphonate-associated Osteonecro-sis of the jaw: A guide for the general dental practitioner. Dent Update. 2006; 33(5): 270-272.
Barrientos FJ, Peral B, de la Peña G, et al. Osteonecrosis of the jaws induced by bisphosphonates: Prevention and therapeu-tic attitude. Rev Esp Cir Oral y Maxillofac. 2007; 29(5): 295- 308. doi: http://dx.doi.org/10.4321/S1130-05582007000500002
Edwards BJ, Hellstein JW, Jacobsen PL, Katlman S, Mariotti A, Migliorati CA, Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advi-sory statement from the American Dental Asociation Council on Scientific Affairs. J Am Dent Assoc. 2008; 139: 1674-1647. doi: 10.14219/jada.archive.2008.0110
Hasegawa T, Shinshou Ri, Umeda M, et al. Cols. The obser-vational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. J Craniomaxil-lofac Surg. 2013; 41: 558-563. doi: 10.1016/j.jcms.2012.11.023
Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncology. 2012; 48: 817-821. doi: 10.1016/j.oraloncology.2012.03.009
Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA,Woo SB. Conservative management of bisphosphonates-re-lated osteonecrosis of the jaws: Staging and treatment outcomes. Oral Oncology. 2013; 49: 977-983. doi: 10.1016/j.oraloncol-ogy.2013.05.012
Marín Fernández AB, Arjona Giménez C, de Dios Navarrete J. Osteonecrosis de los maxilares asociada al uso de bifosfona-tos: A propósito de cinco casos. Rev Osteoporos Metab Miner. 2012; 4(1): 37-41.
Carbonell Pastor E, Díaz Fernández JM, Murillo Cortés J. Treatment of osteonecrosis of the jaw by bisphosphonates. In: Bagan JV, ed. Osteonecrosis of the jaw by bisphosphonates. Va-lencia, Spain: Oral Medicine SL; 2008: 71-90.
American Dental Association Council on Scientific Affairs. Expert panel recommendations: Dental management of patients receiving oral bisphosphonate therapy. J Am Dental Assoc. 2006; 137: 1144-1150.
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw. 2009.
AAOMS position paper on BRONJ. JOMS. 2007; 65: 369- 376. 2009 Update. JOMS. 2009; 67(1): 2-12.
Ruggiero SL, Fantasía J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagno-sis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(4): 433-441.
Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of second-ary osteoporosis: A crossectional study. BMJ. 1996; 313: 344- 346. doi: 10.1136/bmj.313.7053.344
Recommendations for the assessment and treatment of pri-mary osteoporosis in women of the Community of Madrid. De-partment of Pharmacy and Health Products. Madrid. 2008.
Carbonell C. Papel of bisphosphonates in preventing and treating osteoporosis. It butlletí dínformació therapeutic. Barce-lona. 2004; 16(5): 19-24.
Clinical practice guidelines in postmenopausal osteoporo-sis, glucocorticoid and male. Committee of Experts SEIOMM. Special / Rev.OsteoporosisMetab documents. Miner. 2009; 1(1): 53-60.
Fresco ER, Ponte FR, Aguirre UM. Bisphosphonates and Oral Pathology II. Osteonecrosis of the jaws: Review of the lit-erature up to 2005. Med Oral Patol Oral Cir Bucal. 2006; 11: 265-270.
Del Castillo Pardo de Vera JL, García de Marcos JA, Arroyo Rodríguez S, Galdeano Arenas M, Calderón Polanco J. Osteo-necrosis of the jaws associated with the use of bisphosphonates. Rev Esp Cir Oral y Maxilofac. 2007; 29(5): 295-308.
Escobar López EA, López López J, Marques Soares MS, ChimenosKüstner E. Osteonecrosis of the jaw associated with bisphosphonates: a systematic review. 2007; 23(2): 91-101.
Naik NH, Russo TA. Bisphosphonates-related osteonecrosis of the jaw: The role of Actinomyces. Clin Infect Dis. 2009; 49: 1729-1732. doi: 10.1086/648075
Cristian P, Ruiz-Bravo E, Regojo R, Tarín V, Alonso S, Pérez-Míes B. Osteonecrosis of the jaws associated with Acti-nomyces infection and treatment with bisphosphonates. Rev Esp Patol. 2013; 46(3):153-157.
Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-re-lated osteonecrosis of the jaw: A report of 32 cases. Oral Oncolo-gy. 2012; 48: 469-474. doi: 10.1016/j.oraloncology.2011.12.004
Soydan SS, UcKan S. Management of bisphosphonate- re-lated osteonecrosis of the jaw with a platelet-rich fibrin mem-brane: Technical Report. J Oral Maxillofac Surg. 2013; 1-5.
Longo F, Guida A, Aversa C, et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literatura. Int J Dent. 2014; 2014: 7. doi: 10.1155/2014/298945
Hernández Vigueras S, Jané-Salas E, Pérez Tomás R, López-López J. Osteonecrosis of the jaws associated with use of bisphosphonates: A review of 491 cases. Av. Odontoestomatol. 2012; 28(4): 199-209. doi: 10.4321/S0213-12852012000400005
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Dentistry (DOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.